Twi Pharmaceuticals Inc., of Tapiei, entered a settlement agreement with Endo Pharmaceuticals Inc., of Malvern, Pa., Teikoku Seiyaku Co. Ltd., of Kagawa, Japan, and Teikoku Pharma USA Inc. to settle outstanding patent litigation related to Twi's lidocaine topical patch 5 percent product. The FDA is reviewing an abbreviated new drug application for Twi's product that, if approved, would be a generic version of Endo's Lidoderm.